Recce Pharmaceuticals Ltd (ASX:RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics designed to address the urgent global health problem of antibiotic resistant superbugs.
The company’s antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs.
Recce executive director James Graham will talk about the company’s progress and plans at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4 along with four other companies.
Fighting antibiotic resistant superbugs
Recce’s patented lead candidate RECCE 327, wholly owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.
The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.
Efficacy against MRSA superbug
RECCE 327 recently showed significant efficacy against the MRSA superbug in the treatment of burns wound infection in an animal model.
The study was undertaken in co-operation with an established Australian teaching hospital, by an independent contract research organisation.
Top line results showed significant in vivo antibacterial activity against Methicillin-Resistant Staphylococcus aureus (MRSA – superbug) in rats with topical burns: RECCE 327 reduced bacterial load and enhanced wound closure.
A separate human skin model showed the antibiotic was non-irritating, even at high concentrations.
Broad range of clinical treatments
Recce chairman Dr. John Prendergast said at the time of publishing the study results: “These data demonstrate that RECCE antibiotics has great potential to be applied in a broad range of clinical treatment settings.
“With significant data synergies from our lead indication in the treatment of sepsis, to another area of urgent unmet need, these new results support Recce’s potential to address the increasing threat of antibiotic resistant superbugs.”
Five companies presenting
Register now for the CEO Sessions: